Patent ID: 11965021
Assignee: EUREKA THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An immune cell comprising:
a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising:
i) an antigen binding module that specifically binds to a target antigen; and
ii) a TCR module (TCRM), wherein the TCRM comprises a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM,
wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; and
wherein the caTCR further comprises a stabilization module comprising a first stabilization domain and a second stabilization domain, wherein the stabilization module is selected from the group consisting of a CH1-CL module, a CH2-CH2 module, a CH3-CH3 module, and a CH4-CH4 module;
and

b) a chimeric signaling receptor (CSR) comprising:
i) a ligand-binding module that is capable of binding or interacting with a target ligand;
ii) a transmembrane module; and
iii) a co-stimulatory immune cell signaling module that is capable of providing a co-stimulatory signal to the immune cell,
wherein the ligand-binding module and the co-stimulatory immune cell signaling module are not derived from the same molecule, wherein the CSR lacks a functional primary immune cell signaling domain, and wherein the co-stimulatory immune cell signaling module is derived from CD30;
wherein the immune cell is a T cell.